Human medicines European public assessment report (EPAR): Nuwiq, simoctocog alfa, Date of authorisation: 22/07/2014, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid Teva, zoledronic acid, Date of authorisation: 16/08/2012, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Bavencio, avelumab, Date of authorisation: 18/09/2017, Revision: 23, Status: Authorised

Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 April 2026

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR): Ceprotin, human protein C, Date of authorisation: 16/07/2001, Revision: 21, Status: Authorised

List of eligible industry stakeholder organisations

EMA closed on Whit Monday, 25 May

Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations

Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - November 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 November 2026, 14:00 (CET) to 26 November 2026, 18:00 (CET)